



ARAŞTIRMA / RESEARCH

Expression levels of KCNQ1 and KCNQ3 genes in experimental epilepsy model

Deneysel epilepsi modelinde KCNQ1 ve KCNQ3 genlerinin ekspresyon düzeyleri

Özlem Coşkun¹ , Özlem Öztopuz¹ , Turgay Çokyaman² 

¹Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi, Biyofizik Anabilim Dalı, ²Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çanakkale, Turkey

Cukurova Medical Journal 2020;45(4):1580-1586

Abstract

Purpose: Status epilepticus (SE) is a highly common neurological disease in children, with recurrent generalized convulsions for more than 30 minutes, and when not controlled, neuronal damage occurs in the brain. The aim of this study was to evaluate the changes in KCNQ1 and KCNQ3 gene expression levels in the acute period after SE.

Materials and Methods: In rats, an experimental SE model was created with Li-Pc. Study; female Wistar albino [250–350 g, 21 (n=7)] rats were used in 3 groups as SE, control and sham groups. The total RNA obtained from brain tissues was converted to cDNA, and gene expression levels of KCNQ1 and KCNQ3 genes were assessed by quantitative real-time PCR (qRT-PCR) method.

Results: Statistically in SE group; compared to the control and sham groups, a significant difference was observed in the gene expression levels of the KCNQ1 and KCNQ3 ion channels. The KCNQ1 and KCNQ3 gene expression levels of the experimental group was found higher than the other groups.

Conclusion: Determining the changes in mRNA expression levels of genes encoding K⁺ ion channels will help to better understand the pathological mechanisms that occur during epilepsy. In the SE experimental model created, it is believed that an increase in mRNA expression of KCNQ1 and KCNQ3 will lead to drug therapy studies planned for the future.

Keywords: Epilepsy brain, Li-pilocarpine, status epilepticus (SE), KCNQ1, KCNQ3, rat

Öz

Amaç: Status epilepticus (SE) 30 dakikadan daha uzun süre tekrarlayan jeneralize konvulziyonlarla birlikte çocuklarda oldukça yaygın bir şekilde görülen nörolojik bir hastalıktır ve kontrol edilmediğinde, beyinde nöronal hasarlar meydana gelir. Bu çalışmanın amacı SE sonrası akut dönemde KCNQ1 ve KCNQ3 gen ekspresyon seviyelerindeki değişiklikleri değerlendirmektir.

Gereç ve Yöntem: Sıçanlarda Li-Pc ile deneysel SE modeli oluşturuldu. Çalışmada; SE, kontrol ve sham grupları olmak üzere 3 grupta dişi Wistar albino [250–350 gr, 21 adet (n=7)] sıçan kullanıldı. Beyin dokularından elde edilen total RNA, cDNA'ya çevrilerek KCNQ1 ve KCNQ3 genlerinin kantitatif gerçek zamanlı PCR (qRT-PCR) yöntemi ile gen ekspresyon değişimleri değerlendirildi.

Bulgular: İstatistiksel olarak SE grubunda; kontrol ve sham grubuna kıyasla KCNQ1 ve KCNQ3 genlerinin ekspresyon seviyelerinde anlamlı oranda farklılık görüldü. Deneysel grubunun KCNQ1 ve KCNQ3 gen ekspresyon düzeyleri diğer gruplardan yüksek bulundu.

Sonuç: K⁺ iyon kanallarını kodlayan genlerin mRNA ekspresyon seviyelerindeki değişikliklerin belirlenmesi epilepsi sırasında oluşan patolojik mekanizmaların daha iyi anlaşılmasına yardımcı olacaktır. Oluşturulan SE deneysel modelde KCNQ1 ve KCNQ3 mRNA ekspresyonlarında artış saptanması ileride yapılması planlanan tedaviye yönelik ilaç çalışmalarına yol göstereceğine inanılmaktadır.

Anahtar kelimeler: Epilepsi, beyin, Li-pilokarpin, status epilepticus (SE), KCNQ1, KCNQ3, sıçan

INTRODUCTION

Ion channels play key roles in the production of membrane potential and function in various cellular

activities such as signal transduction, neurotransmitter release, muscle contraction, hormone secretion, hydro electrolyte balance, growth, motility and apoptosis¹. These channels can

Yazışma Adresi/Address for Correspondence: Dr. Özlem Coşkun, Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi, Biyofizik Anabilim Dalı, Çanakkale, Turkey E-mail: ozlemcd38@hotmail.com

Geliş tarihi/Received: 23.06.2020 Kabul tarihi/Accepted: 26.08.2020 Çevrimiçi yayın/Published online: 30.10.2020

consist of a single protein or a group of some subunits, each of which is a protein encoded by a different gene. About 600 ion channel genes have been recognised. The ion channels can be associated with a variety of hereditary diseases associated with hyperexcitability, particularly epilepsies^{2,3}.

Epilepsy is a neurological disease characterized by spontaneous and recurrent seizures caused by excessive, abnormal and hypersynchronous neuronal activity⁴. Epilepsy patients carry 18-24 times higher risk of Sudden Unexpected Death in Epilepsy (SUDEP) than the normal population⁵. SUDEP is the sudden and unexpected death of cases where witnesses may or may not be healthy without SE (Status Epilepticus) epilepsy patients from other directions. In SUDEP cases, no cause of death can be detected in postmortem examinations. However previously it was shown that SUDEP may be associated with cardioautonomic-respiratory dysfunction and cardiac arrhythmias. In this context, the relevance between cardiac arrhythmias and epileptic seizures was first shown by Hartmann et al⁶. In this study, the relationship between Na⁺ channel (SCN5A) and long QT syndrome was revealed. In the following years, it was concluded that there is a connection between K⁺ channels and cardiac arrhythmias⁷.

K channels are ion channels encoded by more than 70 genes found in every cell of the organism⁸. Potassium channels are included in the formation and transmission of electrochemical signals in cells⁹. The most known K⁺ channels encoded gene associated with epilepsy are KCNQ2 and KCNQ3 and mutations in these genes expressed in the brain are known to cause refractory epilepsies in the neonatal period¹⁰.

The KCNQ1 gene has very similar homology with KCNQ2 and 3 and it has been demonstrated that mutations in this gene cause Long QT syndrome (LQT)¹¹. The KCNQ1 gene has been expressed in the brain and its association with epilepsy has been recently demonstrated in a limited number of experimental studies¹².

SE is defined as seizure activity continues at least 30 minutes without interruption and causes neuronal cell death. It is an emergency that must be intervened due to the risk of mortality¹³. SE causes neuronal damage to the brain tissue through mechanisms such as oxidative stress, inflammation and mitochondrial dysfunction¹⁴. In in vitro and in vivo investigations,

the function of K⁺ ion channels in epilepsy has not been fully elucidated. This is the first study to show the changes in K⁺ ion channel expression in the epileptic animal model. We hypothesized that detecting variations in the expression of K⁺ ion channels would contribute to the development of therapeutic drugs. For this purpose, we investigated the changes in KCNQ1 and KCNQ3 gene expression levels in the acute period after SE.

MATERIALS AND METHODS

Animals model

In this experiment 21 adult female rats were used. The experiment process were permitted by ÇOMÜ Animal Experiments Local Ethics Committee (HADYEK-2020-2000038720). This study was approved by the university ethics committee and all procedures performed in the study were carried out in accordance with the 1964 Helsinki Declaration standards. Along the study, all rats were kept at 23°-25°C temperature in 12 hours light/12 hours dark rhythm (light, 08:00-20:00, dark 20: 0-08:00).

Chemicals

Pilocarpine hydrochloride and lithium chloride were purchased from Sigma Aldrich. Diazepam and atropine were used from commercial form.

Experimental design

A total of 21 female rats were randomly separated into three groups (n = 7)

Group SE: Only SE was performed and the treatment was terminated at the 24th hour following SE.

Group Control: No intervention was performed. Normal care and nutrition was given.

Group Sham: 2 ml SF application was performed ip for 48 hours with an interval of 12 hours from the beginning of the study.

After sacrifice, rat brains samples were taken for genetic analysis in all groups.

In the experimental model, the pilocarpine (Pi) initial dose was 200 mg/kg/dose (ip) to minimize the mortality rate, and the occurrence of stage 4/5 seizure activity was observed according to the Racine scale. An additional 100 mg/kg/dose of Pi was administered to rats that did not show Racine stage 4/5 seizure activity at the initial dose. In order to

decrease mortality, rats with 60 minutes or more Racine stage 4/5 seizure activity were treated with 5 mg/kg/dose diazepam (ip) to end the seizure. To increase pilocarpine (Pi) sensitivity and reduce lethal side effects, 127 mg/kg/dose Li with physiological saline was administered 24 hours before administration by sc. In addition, 1-5 mg/kg/dose of atropine sulfate (sc) was made 30 minutes before SE induction to reduce peripheral cholinomimetic effects due to Pi.

Stages of Racine scale are as follows;

Stage 1: Around the face and mouth movements, steepening feathers

Stage 2: Head-shaking movements

Stage 3: Clone of the front extremities

Stage 4: Clone of front extremities with rearing and seizure

Stage 5: Cloning of the extremities (generalized motor convulsions) with rearing and subsequent falling and seizure¹⁵⁻¹⁸.

mRNA isolation and quantitative real-time RT-PCR analysis

Genes expressions were evaluated by quantitative real-time RT-PCR. Total RNA was isolated from 10-30 mg brain tissue using the QIAamp RNA column (Ambion Pure Link RNA Mini Kit) according to the kit protocol. The quality and amount of mRNA was determined according to the 260/280 absorbance rate using the Nano Drop ND-1000 Spectrophotometer. Reverse transcription (High Capacity cDNA Reverse Transcription Kit) was performed using the cDNA synthesis kit. Synthesized cDNA samples were used for quantitative real-time polymerase chain reaction (qRT-PCR).

Gene expression levels were analyzed by qRT-PCR (ABI Stepone) using Applied Biosystems™ TaqMan® Gene Expression (Thermo Fisher Scientific, USA). β -actin was used for the normalization of genes. Gene expressions were determined using Ct values and fold changes were evaluated by the $2^{-\Delta\Delta Ct}$ method. Primer ID numbers for KCNQ1, KCNQ3 and β -actin are Rn00583376_m1, Rn00580995_m1, Rn00667869_m1 respectively (Thermo Fisher).

Statistical analysis

All results were assessed by SPSS Statistics for Windows, Version 20.0 (Armonk, New York, USA:

IBM Corp.) Mean and standard error values were used to present the descriptive data. All groups were compared by One Way Anova test, followed post-hoc Tukey's test and $p < 0.05$ was statistically significant. Genes expression level were evaluated $2^{-\Delta\Delta Ct}$ method [$\Delta\Delta Ct = (Ct \text{ Target gene} - Ct \text{ reference gene})$].

RESULTS




Fig 1. Gen expression levels of KCNQ1 in all groups of rat brain tissue. After normalized them RNA level with β -Actin, it is showed as a $2^{-\Delta\Delta Ct}$ relative expression.

One-way ANOVA was used to compare gene expressions levels between groups and results were evaluated according to the post-hoc Tukey's test. *:different from Control and Sham groups, $p < 0.00$.

Potassium voltage-gated channels subfamily Q member 1 (KCNQ1): Gene expression levels of KCNQ1 in rat brain tissue are presented in Fig 1. SE group was shown to have KCNQ1 gene expression at higher levels than all other groups. This difference was found to be significant with post-hoc analyses ($p < 0.00$).




Fig 2. Gen expression levels of KCNQ3 in all groups of rat brain tissue. After normalized them RNA level with β -Actin, it is showed as a $2^{-\Delta\Delta Ct}$ relative expression.

One-way ANOVA was used to compare gene expressions levels between groups and results were evaluated according to the post-hoc Tukey's test. *:different from Control and Sham groups, $p < 0.05$.

Potassium voltage-gated channel subfamily Q member 3 (KCNQ3): KCNQ3 gene expression levels in rat brain tissue are shown in Fig 2. The highest gene expression level was found in the SE group, it was found to be statistically different from the control and sham groups ($p < 0.05$). Apart from SE, the KCNQ3 gene expression levels in the groups were similar and no difference was detected.

DISCUSSION

In our study, the mRNA changes of the K^+ ion channels (encoded by KCNQ1 and KCNQ3) in the brain tissue of the SE modeled rats were examined and an increase was observed in the SE group compared to the control and sham groups. This gene expression profile of KCNQ1 and KCNQ3 may reveal their contribution to hyperexcitability. In previous studies, KCNQ1 has been associated with long QT syndrome and deafness and epilepsy¹⁹⁻²¹. KCNQ-mediated potassium flow also called M current, has been reported to be important in regulating neuronal excitability of the central nervous system and a 25% reduction in this current may cause epilepsy²². In recent years, gene defects fundamental several forms of epilepsy have been identified and it has been reported that most of the genes encoding these ion channels play an important role in the pathogenesis of idiopathic epilepsy. Various epileptic phenotypes have been connected with malfunctions of K^+ ion channels. The channels play an essential role in neuronal stimulation, and their significance is correlated to the levels of expression in the subcellular area, cell or domain²³.

There are more than 70 potassium ion channel genes in humans, however some of them have been associated with neurological disorder. Several KCNQ genes mutations are associated with diseases such as cardiac arrhythmia, deafness, and epilepsy show vary physiological roles of KCNQ channels. In addition, several KCNQ isoforms can combine to form heteromeric channels that underlie the M-stream, an important regulator of neuronaleability²⁴. Brain-expressing KCNQ5 alone or together with KCNQ3 can form M-type channels and make all these subunits and several heteromers interesting targets for drug development²⁵.

In different parts of the brain KCNQ2/KCNQ3 channels appear to be the main factor of "M" currents blocked by various neurotransmitters, including acetylcholine (ACh) through muscarinic

receptors. K^+ ion channels represent important targets for the new pharmacological control of abnormal electrical discharges and synaptic function in the brain. Therefore, more effort should be studied to find new K^+ ion channel regulators and gene therapies to improve symptoms of the disease⁸. KCNQ1 is expressed in some tissues, including the heart muscle, and many epithelium, but KCNQ1 mutations effect serious outcomes in a little tissue, mainly depending on the degree of current reduction²⁶.

The four other related channel proteins (KCNQ2, -3, -4 and -5) provided interesting information last years. Mutations in the KCNQ genes form the basis of various diseases and lead to electrical hypersensitivity in cardiac arrhythmia and epilepsy, disorders of transepithelial transport in congenital deafness, and possibly cell degeneration in progressive hearing loss²⁷. Although previous studies on the KCNQ family Delmas and Brown et al. describe KCNQ1 channels as non-neuronal channels, gene expression studies clearly demonstrate the expression of KCNQ1 in the central nervous system; Luo et al. showed expression of KCNQ1 in the human brain. Goldman et al. reported the expression of KCNQ1, including glia cells of the white matter tracts in the frontal, temporal, parietal and occipital lobes, as well as in the hippocampus and spinal cord²⁸⁻³⁰.

Epilepsy is a brain disorder that frequently generates muscle spasms, convulsions and loss of consciousness by irregular firing of neuronal networks in the brain⁸. Epileptic seizures are stimulated by irregular focal or synchronous electrical discharges within the central nervous system (CNS). In linkage between neurons, balance is modulated by a network of stimulating and blocking circuits. Disruption of both excitatory and inhibitory systems can collapse the balance and cause epileptic discharges. Axonal conduction is one of the two main systems fundamental the electrophysiological excitability and communication substantiates through action potentials and cell-to-cell signal transmission through synaptic transmission. Axonal conduction of action potentials is the fundamental mechanism for the cell-to-cell communication through synaptic transmission³¹.

SE is a neurological emergency identified with recurrent seizures that last longer than 30 minutes without returning to the central functions of the central nervous system. This definition may include

having two or more seizures in which seizures are not fully achieved³². During SE seizures, as a result of changes in the function and/or synthesis of ion channels induce acute changes in neuron excitability during seizures. This leads to increase in dendritic stimulation and a greater postsynaptic potential stimulus³³. Since cells with epilepsy that cause gliosis, damage their ability to buffer extracellular K^+ ions cause an increase in K^+ ions outside the cell, leading to a lowered excitability threshold and epilepsy seizures. In addition, extracellular K^+ ion concentration increases in epileptogenic regions due to the decrease in $Na^+-K^+/ATPase$ activity. In this way, the neurons will be stimulated and give rise occurrence of discharges and spread more easily³⁴.

In another study, the expression of voltage-gated potassium channel 4.2 (Kv4.2) and voltage-gated potassium channel 4-interacting protein (KChIP1) in rats formed with Li-pilocarpine were investigated. It was reported that 1 day after SE, Kv4.2 expression increased in both the hippocampus and cortex and KChIP1 expression increased in the hippocampus³⁵. These results appear to be compatible with our results (Fig 1, Fig 2).

KCNQ3 is constantly expressed in neuronal cells in the brain. The highest expression levels of KCNQ3 have been reported to be noted in the cerebral cortex, thalamus, hippocampus and caudate / putamen. Some nuclei of the amygdala and the hypothalamus have been found to show KCNQ3 expression³⁶. KCNQ2 and KCNQ3 were determined by homology to KCNQ1, as well as positional cloning in families with benign familial neonatal convulsions (BFNC), a form of neonatal epilepsy. These are mainly expressed in neuronal tissue, involving sympathetic ganglia, and the expression patterns in the brain overlap substantially. Similar to KCNQ1, both KCNQ2-3 give slowly activated K^+ currents in depolarization^{37,38}.

Surprisingly, however, studies on which potassium ion channel variants can be functionally classified by electrophysiological and pharmacological approaches are limited and rather inconsistent. It can be assumed that such differences are related to variety distinct operations and quantification procedures. Notwithstanding, systematic research on the comparative significance of the components for channel expression and role in the animal brain is rare in the literature and transformation studies comparing informations from neonatal and adult brain with human details are sufficient. In epilepsy,

determining the molecular mechanisms and genetic factors that cause disease, understanding the physiopathology, and developing new treatment proposals in the light of the defined details are important in terms of revealing drug resistance mechanisms, especially in drug-resistant epilepsies. In epilepsy, determining the molecular mechanisms and genetic factors are important in terms of revealing drug resistance mechanisms³⁹.

Considering that the majority of antiepileptics act directly or indirectly through ion channels or receptors, a treatment approach becomes even more important. Today, with the classical antiepileptic treatment approach, the genetic mutation that can be detected in the patient is also taken into account⁴⁰.

As a result, the discovery of K^+ ion channels that encode genes that affect susceptibility and disease progression will provide insight into the molecular events of epileptogenesis, improve molecular diagnostic use, and set new therapeutic targets for the treatment of human epilepsy⁴¹. Understanding the mechanism of potassium ion channels functioning to cause epilepsy will give new insights into the internal work of neural circuits and help develop new therapies. The pathophysiology of epileptic seizures is not fully known. Also, the same pathophysiology is not valid in all epileptic seizures. Anticonvulsants block voltage sensitive Na^+ ion channels, reducing the duration of epileptic discharges and action potentials that occur with each discharge⁴².

The molecular mechanisms regulating K^+ ion channels are largely unknown. There is a need for future preclinical experimental studies to fully understand the events in the voltage dependent channels during epilepsy and to solve the mechanisms of the drugs used in the treatment through these channels. Our study is a preliminary study which is a preliminary study examining the changes in gene expression levels of K^+ ion channels in the experimental animal model performed with status epilepticus with Li-pilocarpine. In future studies, experimental studies are planned on the changes in K^+ ion channels for treatment by creating new experimental models with convulsive drugs. The main limitations of the study are that there are no similar studies in the literature and that the expression level changes of KCNQ1 and KCNQ3 genes in the epileptic model are not known. A more detailed examination of K^+ ion channels will shed light on the elimination of effective mechanisms during seizure and treatment in epilepsy. In order to obtain more

detailed findings, the correlation between ion channels can be evaluated by examining the changes in other ion channels in the SE model. We believe that our study will be the basis for further studies in this field.

In conclusion, the datas obtained in the experimental animal model in our study will enable us to understand the mechanisms by which specific channelopathies contribute to epilepsy and will lead to advances in the treatment strategies of the disease. Although the disorder of K⁺ ion channels is associated with many neurological illness, its role is not fully understood. Changes in the expression of K⁺ ion channels will help to understand its role in the pathogenesis of epilepsy. Regulation of K⁺ ion channel expression is important for the development of drugs and treatments. Understanding the function of K⁺ ion channel expression in experimental and clinical studies will contribute to the development of appropriate therapeutic strategies in epileptic diseases.

Yazar Katkıları: Çalışma konsepti/Tasarımı: TÇ, ÖC, ÖÖ; Veri toplama: ÖC, ÖÖ; Veri analizi ve yorumlama: ÖC, ÖÖ, TÇ; Yazı taslağı: ÖC, ÖÖ; İçerğin eleştirel incelenmesi: ÖC, ÖÖ; Son onay ve sorumluluk: ÖC, ÖÖ, TÇ; Teknik ve malzeme desteği: ÖC, ÖÖ; Süpervizyon: ÖC, ÖÖ; Fon sağlama (mevcut ise): yok.

Etik Onay: Bu çalışma Çanakkale Onsekiz Mart Üniversitesi Hayvan Deneyleri Yerel etik kurulu tarafından onaylanmıştır (HADYEK-2020-2000038720).

Hakem Değerlendirmesi: Dış bağımsız.

Çıkar Çatışması: Yazarlar çıkar çatışması beyan etmemişlerdir.

Finansal Destek: Yazarlar finansal destek beyan etmemişlerdir.

Author Contributions: Concept/Design : TÇ, ÖC, ÖÖ; Data acquisition: ÖC, ÖÖ; Data analysis and interpretation: ÖC, ÖÖ, TÇ; Drafting manuscript: ÖC, ÖÖ; Critical revision of manuscript: ÖC, ÖÖ; Final approval and accountability: ÖC, ÖÖ, TÇ; Technical or material support: ÖC, ÖÖ; Supervision: ÖC, ÖÖ; Securing funding (if available): n/a.

Ethical Approval: This study was approved by Çanakkale Onsekiz Mart University Animal Experiments Local Ethics Committee

Peer-review: Externally peer-reviewed.

Conflict of Interest: Authors declared no conflict of interest.

Financial Disclosure: Authors declared no financial support

REFERENCES

- Brading AF. Spontaneous activity of lower urinary tract smooth muscles: correlation between ion channels and tissue function. *J Physiol.* 2006;570:13-22.
- Lerche H, Jurkat-Rott K, Lehmann-Horn F. Ion channels and epilepsy. *Am J Med Gene.* 2001;106:146-59.
- Iannetti P, Farello G, Verrotti A. Editorial-Channelopathies: a link between brain and heart: the model of epilepsy. *Eur Rev Med Pharmacol Sci.* 2017;21:5523-26.
- Vizuete AFK, Hennemann MM, Gonçalves CA, De Oliveira DL. Phase-dependent astroglial alterations in Li-pilocarpine-induced status epilepticus in young rats. *Neurochemical Res.* 2017;42:2730-42.
- Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. *Epilepsy Res.* 2007;75:192-6.
- Hartmann M, Decking UKM. Blocking Na⁺-H⁺ exchange by cariporide reduces Na⁺-overload in ischemia and is cardioprotective. *J Mol Cell Cardiol.* 1999;31:1985-95.
- Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. *Cell.* 1995;80:805-11.
- D'Adamo MC, Catacuzzeno L, Di Giovanni G, Franciolini F, Pessia M. K⁺ channelopathy: progress in the neurobiology of potassium channels and epilepsy. *Front Cell Neurosci.* 2013;7:134.
- Jespersen T, Grunnet M, Olesen SP. The KCNQ1 potassium channel: from gene to physiological function. *Physiology.* 2005;20:408-16.
- Berkovic SF, Mulley JC, Scheffer IE, Petrou S. Human epilepsies: interaction of genetic and acquired factors. *Trends Neurosci.* 2006;29:391-97.
- Rogawski MA. KCNQ2/KCNQ3 K⁺ channels and the molecular pathogenesis of epilepsy: implications for therapy. *Trends Neurosci.* 2000;23:393-98.
- Nashef L, Hindocha N, Makoff A. Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms. *Epilepsia.* 2007;48:859-71.
- Kim JE, Yeo SI, Ryu HJ, Kim MJ, Kim DS, Jo SM et al. Astroglial loss and edema formation in the rat piriform cortex and hippocampus following pilocarpine-induced status epilepticus. *J Comp Neurol.* 2010;518:4612-28.
- Liu J, Wang A, Li L, Huang Y, Xue P, Hao A. Oxidative stress mediates hippocampal neuron death in rats after lithium-pilocarpine-induced status epilepticus. *Seizure.* 2010;19:165-72.
- Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. *J Neurosci Methods.* 2008;172:143-57.
- Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. *Electroencephalogr Clin Neurophysiol.* 1972;32:281-94.
- Glien M, Brandt C, Potschka H, Voigt H, Ebert U, Löscher W. Repeated low-dose treatment of rats with pilocarpin: low mortality but high proportion of rats developing epilepsy. *Epilepsy Res.* 2001;46:111-9.
- Suhomeleva L, Baldwin RA, Kubova H, Thompson KW, Sankar R, Wasterlain CG. Treatment of experimental status epilepticus in immature rats. *Pediatr Res.* 2006;59:237-43.
- Hong K, Piper DR, Diaz-Valdecantos A, Brugada J, Oliva A, Burashnikov E et al. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. *Cardiovasc Res.* 2005;68:433-40.
- Chang Q, Wang J, Li Q, Kim Y, Zhou B, Wang Y et

- al. Virally mediated Kcnq1 gene replacement therapy in the immature scala media restores hearing in a mouse model of human Jervell and Lange-Nielsen deafness syndrome. *EMBO Mol Med.* 2015;7:1077-86.
21. Tiron C, Campuzano O, Pérez-Serra A, Mademont I, Coll M, Allegue C et al. Further evidence of the association between LQT syndrome and epilepsy in a family with KCNQ1 pathogenic variant. *Seizure.* 2015;25:65-7.
 22. Schroeder BC, Kubisch C, Stein V, Jentsch TJ. Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K⁺ channels causes epilepsy. *Nature.* 1998;396:687-90.
 23. Brenner R, Wilcox KS. Potassium channelopathies of epilepsy. In Jasper's Basic Mechanisms of the Epilepsies. 4th edition. 2012.
 24. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. *Nat Rev Neurosci.* 2000;1:21-30.
 25. Seebohm G, Scherer CR, Busch A, Lerche C. Identification of specific pore residues mediating KCNQ1 inactivation: a novel mechanism for long QT syndrome. *J Biol Chem.* 2001;276:13600-5.
 26. Chouabe C, Neyroud N, Richard P, Denjoy I, Hainque B, Romey G, Barhanin J. Novel mutations in KvLQT1 that affect I_{Ks} activation through interactions with Isk. *Cardiovas Res.* 2000;45:971-80.
 27. Wang Q, Curran M, Splawski I, Burn TC, Millholland JM, VanRaay TJ et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. *Nat Genet.* 1996;12:17-23.
 28. Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. *Nat Rev Neurosci.* 2005;6:850-62.
 29. Luo X, Xiao J, Lin H, Lu Y, Yang B, Wang Z. Genomic structure, transcriptional control, and tissue distribution of HERG1 and KCNQ1 genes. *Am J of Physiol-Heart Circulatory Physiol.* 2008;294(3):H1371-H1380.
 30. Goldman AM, Glasscock E, Yoo J, Chen TT, Klassen TL, Noebels JL. Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. *SciTransl Med.* 2009;1:2ra6-2ra6.
 31. Akay A, Sümer-Turanlıgil NC, Uyanıkgil Y. İyon kanalları ve epilepsi patojenezindeki rolleri. *Arşiv Kaynak Tarama Dergisi.* 2010;19:72-84.
 32. Blume WT, Lüders HO, Mizrahi E, Tassinari, van Emde Boas W, Engel Jr, Ex-officio J. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. *Epilepsia.* 2001;42:1212-18.
 33. Shah MM, Anderson AE, Leung V, Lin X, Johnston D. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. *Neuron.* 2004;44:495-508.
 34. Sonat FA, Balcı F. Sıçanlarda pilocarpin ile oluşturulan epilepside topiramatin nöronlar üzerine etkisi. *Uludağ Üniversitesi Veteriner Fakültesi Dergisi.* 2010;29:1-7.
 35. Su T, Cong WD, Long YS, Luo AH, Sun WW, Deng WY et al. Altered expression of voltage-gated potassium channel 4.2 and voltage-gated potassium channel 4-interacting protein, and changes in intracellular calcium levels following lithium-pilocarpine-induced status epilepticus. *Neurosci.* 2008;157:566-76.
 36. Saganich MJ, Machado E, Rudy B. Differential expression of genes encoding subthreshold-operating voltage-gated K⁺ channels in brain. *J Neurosci.* 2001;21:4609-24.
 37. Tinel N, Lauritzen I, Chouabe, Lazdunski M, Borsotto M. The KCNQ2 potassium channel: splice variants, functional and developmental expression. Brain localization and comparison with KCNQ3. *FEBS Lett.* 1998;438:171-76.
 38. Yang WP, Levesque PC, Little WA, Conder ML, Ramakrishnan P, Neubauer MG et al. Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. *J Biol Chem.* 1998;273:19419-423.
 39. Yavuz ENV, Baykan B. Epilepsi, moleküler mekanizmalar ve ilgili nöromediatörler. *Türkiye Klinikleri Neurology-Special Topics.* 2010;3:38-42.
 40. Walker MC, Schorge S, Kullmann DM, Wykes RC, Heeroma JH, Mantoan L. Gene therapy in status epilepticus. *Epilepsia.* 2013;54:43-45.
 41. Villa C, Combi R. Potassium channels and human epileptic phenotypes: an updated overview. *Front Cell Neurosci.* 2016;10:81.
 42. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. *Epilepsia.* 2004;45:1478-87.